L3VLUP
ProSign in

TMO · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TMOJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TMO
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterTMOJNJ
Q3 202029 holders, $38.9bn30 holders, $26.2bn
Q4 202033 holders, $39.2bn32 holders, $26.6bn
Q1 202135 holders, $36.5bn31 holders, $25.3bn
Q2 202133 holders, $38.3bn37 holders, $25.6bn
Q3 202132 holders, $42.6bn40 holders, $24.1bn
Q4 202138 holders, $50.1bn33 holders, $25.2bn
Q1 202232 holders, $43.2bn35 holders, $28.2bn
Q2 202233 holders, $38.9bn33 holders, $26.9bn
Q3 202226 holders, $34.3bn36 holders, $25.4bn
Q4 202229 holders, $37.0bn35 holders, $27.6bn
Q1 202335 holders, $37.1bn42 holders, $24.5bn
Q2 202339 holders, $33.5bn38 holders, $25.0bn
Q3 202339 holders, $32.6bn37 holders, $18.9bn
Q4 202341 holders, $32.7bn31 holders, $19.0bn
Q1 202430 holders, $34.1bn32 holders, $19.7bn
Q2 202438 holders, $30.6bn35 holders, $20.4bn
Q3 202430 holders, $33.8bn28 holders, $22.3bn
Q4 202436 holders, $27.6bn37 holders, $20.4bn
Q1 202531 holders, $24.2bn32 holders, $20.5bn
Q2 202539 holders, $18.8bn31 holders, $18.4bn
Q3 202532 holders, $21.9bn32 holders, $23.7bn
Q4 202532 holders, $29.9bn29 holders, $27.8bn
Q1 202634 holders, $24.4bn34 holders, $35.6bn
Q2 202636 holders, $26.4bn33 holders, $39.1bn
TMO

Thermo Fisher Scientific Inc

Holders
32
Reported value
$21.9bn
Buyers
22
Sellers
13

Breadth +9 among 95 comparable managers.

IndustrialsHealthcare: biopharma and medtech · L3VLUPIndustrials and automation · L3VLUP
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TMO (13)

Artisan Partners LP, Baillie Gifford & Co, Capital World Investors, Farallon Capital Management LLC, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Point72 Asset Management LP, Polen Capital Management LLC, Rokos Capital Management LLP, Soroban Capital Partners LP, Steadfast Capital Management LP, Winton Group Ltd

Only JNJ (13)

Acadian Asset Management LLC, AQR Capital Management LLC, Balyasny Asset Management LLC, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Jane Street Group LLC, Man Group PLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Two Sigma Investments LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →